Rigel Pharmaceuticals Ownership | Who Owns Rigel Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

Rigel Pharmaceuticals Ownership Summary


Rigel Pharmaceuticals is owned by 89.82% institutional investors, 3.36% insiders, and 6.82% retail investors. Blackrock funding, inc. /de is the largest institutional shareholder, holding 10.54% of RIGL shares. Avantis US Small Cap Value ETF is the top mutual fund, with 3.70% of its assets in Rigel Pharmaceuticals shares.

RIGL Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockRigel Pharmaceuticals89.82%3.36%6.82%
SectorHealthcare Stocks 50.62%12.41%36.97%
IndustryBiotech Stocks 49.15%12.15%38.70%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock funding, inc. /de1.94M10.54%$75.89M
Soleus capital management1.84M10.01%$72.12M
Armistice capital1.67M9.08%$65.41M
Vanguard group1.04M5.76%$44.48M
State street1.04M5.65%$40.68M
Vanguard capital management785.11K4.26%$30.71M
American century companies741.72K4.03%$29.02M
Lsv asset management721.67K3.92%$28.23M
Capitolis liquid global markets591.55K3.31%$16.76M
Acadian asset management591.69K3.21%$23.14M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Cm management250.00K6.21%$9.78M
Soleus capital management1.84M2.49%$72.12M
Armistice capital1.67M0.80%$65.41M
Globeflex capital l p112.67K0.56%$4.41M
Pharvision advisers20.52K0.33%$581.39K
Virtus investment advisers35.40K0.32%$1.38M
Centerbook partners lp109.58K0.21%$4.29M
Sierra summit advisors31.88K0.14%$1.25M
Capitolis liquid global markets591.55K0.13%$16.76M
Diadema partners lp22.82K0.11%$892.56K

Top Buyers

HolderShares% AssetsChange
Soleus capital management1.84M2.49%1.83M
Armistice capital1.67M0.80%392.00K
American century companies741.72K0.01%197.29K
Macquarie management195.00K0.01%195.00K
Blackrock funding, inc. /de1.94M0.00%170.91K

Top Sellers

HolderShares% AssetsChange
Blackrock---14.80M
Nuveen asset management---3.22M
Healthcare of ontario pension plan trust fund---1.36M
Stonepine capital management---1.04M
Qube research---343.90K

New Positions

HolderShares% AssetsChangeValue
Macquarie management195.00K0.01%195.00K$7.63M
Sixth street partners management company154.63K0.00%154.63K$6.05M
Centerbook partners lp109.58K0.21%109.58K$4.29M
Axa investment managers32.59K0.00%32.59K$923.39K
Pharvision advisers20.52K0.33%20.52K$581.39K

Sold Out

HolderChange
Financial consulate-10.00
Synergy asset management-15.00
Frazier financial advisors-18.00
Strategic investment solutions, inc. /il-25.00
Harbour investments-40.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 20261603.23%16,538,2993.34%891.19%882.33%5422.73%
Mar 31, 2026152-20.42%15,851,405-1.52%881.11%84-24.32%43-30.65%
Dec 31, 202545-73.53%2,395,282-84.02%130.19%33-68.27%9-80.43%
Sep 30, 202548-61.29%2,467,259-82.23%130.23%24-61.90%14-61.11%
Jun 30, 20251230.82%13,882,606-0.14%771.27%62-3.13%36-5.26%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Avantis US Small Cap Value ETF691.89K3.70%2.77K
State Street® SPDR® S&P® Biotech ETF640.16K3.43%1.47K
Vanguard US Total Market Shares ETF548.78K3.07%-
Vanguard Morn Total Stk Mkt Idx Investor555.85K3.00%13.80K
Vanguard Total Stock Mkt Idx Inv555.85K3.00%13.80K
Vanguard MStar Total Stk Mkt Idx Invest555.85K2.98%-
iShares Russell 2000 ETF471.53K2.52%-8.35K
SPDR® S&P Biotech ETF223.01K1.24%500.00
Nuveen Quant Small Cap Equity R6213.85K1.16%-
Vanguard Institutional Extnd Mkt Idx Tr212.72K1.14%364.00

Recent Insider Transactions


DateNameRoleActivityValue
Jun 22, 2026Ali-Jackson Kamil-Sell$87.50K
May 26, 2026Ali-Jackson Kamil-Sell$72.92K
Feb 20, 2026MOOS WALTER H-Sell$145.44K
Feb 04, 2025Schorno Dean L EVP & Chief Financial OfficerSell$42.60K
Feb 05, 2025Schorno Dean L EVP & Chief Financial OfficerSell$38.02K

Insider Transactions Trends


DateBuySell
2026 Q2-2
2026 Q1-1
2025 Q4--
2025 Q3--
2025 Q2--

RIGL Ownership FAQ


Who Owns Rigel Pharmaceuticals?

Rigel Pharmaceuticals shareholders are primarily institutional investors at 89.82%, followed by 3.36% insiders and 6.82% retail investors. The average institutional ownership in Rigel Pharmaceuticals's industry, Biotech Stocks , is 49.15%, which Rigel Pharmaceuticals exceeds.

Who owns the most shares of Rigel Pharmaceuticals?

Rigel Pharmaceuticals’s largest shareholders are Blackrock funding, inc. /de (1.94M shares, 10.54%), Soleus capital management (1.84M shares, 10.01%), and Armistice capital (1.67M shares, 9.08%). Together, they hold 29.63% of Rigel Pharmaceuticals’s total shares outstanding.

Does Blackrock own Rigel Pharmaceuticals?

BlackRock is not among the top 10 institutional shareholders of Rigel Pharmaceuticals.

Who is Rigel Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Cm management is Rigel Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 6.21% of its assets in 250K Rigel Pharmaceuticals shares, valued at 9.78M$.

Who is the top mutual fund holder of Rigel Pharmaceuticals shares?

Avantis US Small Cap Value ETF is the top mutual fund holder of Rigel Pharmaceuticals shares, with 3.70% of its total shares outstanding invested in 691.89K Rigel Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools